JAMA Medical News Highlights From Kidney Week 2025
7 snips
Nov 21, 2025 Katherine R. Tuttle, a nephrology expert and chair of Kidney Week 2025, dives into crucial advancements in kidney health. She discusses the significant impact of SGLT2 inhibitors in reducing kidney failure and heart-related issues. Hear about a groundbreaking trial showing fish oil can cut mortality by over 50% in hemodialysis patients. Tuttle also highlights promising research on conservative dialysis practices that enhance kidney recovery, and the real-world benefits of semaglutide in minimizing kidney complications in patients with type 1 diabetes.
AI Snips
Chapters
Transcript
Episode notes
CKD Is A Growing Global Health Crisis
- Chronic kidney disease (CKD) has grown to 788 million adults globally and is now the ninth leading cause of death.
- Diabetes and obesity are the main drivers, with diabetes causing half of CKD cases worldwide.
SGLT2 Inhibitors Deliver Broad Kidney Protection
- Meta-analyses show SGLT2 inhibitors cut kidney failure risk by ~40% and heart-failure events by ~25% regardless of diabetes status.
- These drugs also lower all-cause mortality by about 20% and should be broadly implemented.
Consider Fish Oil For Hemodialysis Patients
- Consider prescribing fish oil for patients on hemodialysis given a reported >50% mortality reduction in the trial.
- The treatment is inexpensive, safe, and reasonable to use while awaiting further confirmation.